Wall: And what's the second stock? Gergel: The second stock is GlaxoSmithKline (GSK). Clearly, very well-known as pharmaceutical stock. It's being transformed by deal with Novartis in 2015, which has made them …
Stock Picks
Xifaxan will help Valeant to compete with established GI drug makers like GlaxoSmithKline PLC (GSK), Astellas Pharmaceuticals ... (See also, …
Drug Administration
Merger mania is sweeping the stock market. It seems no company is safe as both ... or a number of buyers may swoop down on GlaxoSmithKline (LSE: GSK) to break up the business and get their hands on the firm’s …
Glaxo
Specifically, Novartis’ stock gained 0.4% during this period ... We remind investors that Novartis broadened its oncology portfolio by acquiring GlaxoSmithKline plc’s (GSK - Free Report) certain oncology products and …
Heart Failure
Chart normalized as of June 2, 2014 Data through March 6, 2017 -60% Innoviva’s current business is focused on collecting royalties from GSK for two respiratory inhalers GSK (Glaxo Group Limited) GSK is responsible for …
Capital
Just four days before Walmsley moves into the top job on April 1, U.S. …
CEO
Success in trials of new drugs for metastatic melanoma propelled the stock of Array Biopharma (NASDAQ ... When Novartis made a deal to acquire …
Array Biopharma
GLAXOSMITHKLINE: Britain's GlaxoSmithKline and U.S.-based ... fiscal easing from the U.S. and a stronger outlook for sterling compounded weakness in the UK stock market. * For more on the factors affecting …
Stock
The aim of Bpifrance is to support businesses, (SMEs, mid-cap companies and larger entities of strategic importance to the French economy), from their seed capital stages up to stock market listing ... Sanofi, GSK, …
Financing Round
Some think, however, that Gilead will have a hard time fending off rival drugs from Merck and GlaxoSmithKline's Viiv Healthcare ... If I'm even close …
Gilead Sciences